Feds approve IMS's purchase of SDI Health

Share this article:

IMS Health's acquisition of SDI Health was officially consummated, and its parent company is moving forward to divest two SDI product lines, as per a settlement order proposed by federal regulators to preserve competition.

The Federal Trade Commission (FTC) put forth the settlement and must approve any buyer. As IMS parent Healthcare Technology Holdings moves forward with its acquisition of SDI through IMS, it must sell the two businesses to a buyer within three months of the completion of the deal, or the FTC may appoint a trustee to sell the assets (the holding company can also ask for an extension).

One of those two product lines, SDI's medical audit business, is part of a two-player market, with IMS controlling 53% and SDI holding a 47% stake. The other product line, the promotional audits business, is also dominated by the two firms—SDI has 68% of the market, and IMS holds a 30% share (Cegedim controls 2%).

Terms of the sale, which IMS announced in January, were not disclosed. “We are excited to have successfully completed our purchase of SDI Health,” said IMS spokesman Gary Gatyas, Jr. “Together, the newly combined company is well positioned to support the needs of our clients.”

On the same day it announced the settlement, the FTC filed a complaint alleging “that the proposed acquisition would substantially increase IMS's share in [the two audit markets],” and eliminate its only significant competitor. The settlement is designed to soothe the regulator's concerns.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric